肺癌药物市场规模、份额和成长分析（治疗方法、癌症类型、分子类型、通路和地区划分）—2026-2033年产业预测

全球肺癌药物市场预计到 2024 年将达到 364 亿美元，到 2025 年将达到 412 亿美元，到 2033 年将达到 1,111 亿美元，预测期（2026-2033 年）的复合年增长率为 13.2%。

肺癌治疗市场正经历显着成长，这主要得益于诊断技术的进步、创新治疗方法的涌现以及全球对肺癌意识的不断提高。政府加大对医疗基础设施和高品质治疗方案的投入是推动市场扩张的关键因素。此外，人们对多样化治疗方法的认知不断提高也进一步刺激了市场需求。同时，可支配收入的增加、新技术研发的持续推进、先进放射线治疗的应用以及开发中国家的经济成长等因素也推动了市场前景。主要企业正致力于创新并强化产品系列，以改善患者的治疗效果。鑑于肺癌的高发病率和高死亡率，它仍然是医疗保健领域持续推进治疗研发的重点领域。

推动全球肺癌药物市场发展的因素

全球肺癌发生率的不断上升对全球肺癌治疗市场产生了重大影响。导致这一激增的主要因素包括吸烟、环境污染和生活方式的改变，这些因素共同造成了确诊病例的显着增加。这种增长推动了对有效治疗方案和旨在改善患者照护的创新治疗方法的需求不断增长。随着医疗系统和研究人员应对这一日益严峻的挑战，对先进治疗方案的需求也在不断演变，从而推动了肺癌治疗市场的发展。

全球肺癌药物市场面临的限制因素

全球肺癌治疗市场面临严峻挑战，主要原因是新治疗方法的核准受到严格监管要求的限制。这项严苛且往往耗时的流程可能会延迟患者获得创新治疗方法的机会，并阻碍疾病管理的及时介入。此外，此类限制性法规可能抑制研发投入，从而限制新治疗方法进入市场。因此，这些障碍不仅减缓了肺癌治疗方法的进展，也阻碍了医疗专业人员为与这种致命疾病作斗争的患者提供最佳护理的努力。

全球肺癌药物市场趋势

全球肺癌治疗市场正经历着向个人化医疗的重大转变，其特点是将基因谱分析和生物标记整合到治疗方案设计中。这种变革性的方法针对每位患者癌症的独特特征，在提高治疗效果的同时，最大限度地减少副作用。因此，对针对个别患者特征量身定制的标靶治疗和免疫疗法的需求日益增长。这一趋势不仅代表着治疗模式的根本性转变，也凸显了持续进行研究和技术进步以优化肺癌治疗患者疗效的必要性。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球肺癌药物市场规模（按疗法和复合年增长率划分）（2026-2033 年）

• 放射线治疗
  • 外束辐射
  • 内放射治疗
  • 全身性治疗
• 标靶治疗
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • 其他的
• 免疫疗法
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
• 化疗
• 其他的

全球肺癌治疗市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 非小细胞肺癌（NSCLC）
• 小细胞肺癌（SCLC）

全球肺癌药物市场规模（按分子类型和复合年增长率划分）（2026-2033 年）

• 低分子化合物
• 生物製药

全球肺癌药物市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房
• 其他的

全球肺癌药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 烷化剂
• 抗代谢物
• EGFR抑制剂
• 有丝分裂抑制剂
• 多激酶抑制剂
• 其他的

全球肺癌药物市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院
• 专科诊所
• 居家医疗
• 其他的

全球肺癌药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Pfizer Inc.（US）
• Novartis AG（Switzerland）
• AstraZeneca PLC（UK）
• Merck & Co. Inc.（US）
• Eli Lilly and Company（US）
• Bristol Myers Squibb Company（US）
• Boehringer Ingelheim International GmbH（Germany）
• Johnson & Johnson（US）
• Amgen Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（US）
• GlaxoSmithKline plc（GSK）（UK）
• Sun Pharmaceutical Industries Ltd.（India）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Dr. Reddy's Laboratories（India）

结论与建议

Global Lung Cancer Therapeutics Market size was valued at USD 36.4 Billion in 2024 and is poised to grow from USD 41.2 Billion in 2025 to USD 111.1 Billion by 2033, growing at a CAGR of 13.2% during the forecast period (2026-2033).

The lung cancer therapeutics market is seeing notable growth, fueled by advancements in diagnostic techniques, innovative treatments, and rising awareness surrounding lung cancer globally. Enhanced government investments in healthcare infrastructure and quality treatment options are critical drivers of this market's expansion. As individuals increasingly recognize the diverse treatment avenues available, market demand intensifies. Furthermore, factors such as rising disposable income, continuous R&D for new technologies, the adoption of advanced radiation therapy, and economic growth in developing nations bolster market prospects. Key players are focusing on innovation and enhancing their product portfolios to improve patient outcomes. Given its high prevalence and significant mortality rate, lung cancer remains a critical area of focus for continued therapeutic advancements in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Therapeutics Market Segments Analysis

Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User and region. Based on Therapy, the market is segmented into Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy and Others. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). Based on Type of Molecule, the market is segmented into Small molecules and Biologics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Therapeutics Market

The rising incidence of lung cancer worldwide significantly influences the global lung cancer therapeutics market. Key contributors to this surge include tobacco use, environmental pollution, and changes in lifestyle, all of which have led to a notable increase in diagnosed cases. This escalation is fostering a heightened demand for effective treatment options and innovative therapies aimed at enhancing patient care. As healthcare systems and researchers strive to address this growing challenge, the need for advanced therapeutic solutions continues to evolve, driving progress within the market dedicated to combating lung cancer.

Restraints in the Global Lung Cancer Therapeutics Market

The Global Lung Cancer Therapeutics market faces significant challenges due to stringent regulatory requirements that govern the approval of new therapies. This rigorous and often lengthy process can delay patient access to innovative treatments, hindering timely intervention in managing the disease. Moreover, such restrictive regulations can deter investment in research and development, limiting the flow of new therapies into the market. As a result, these barriers not only slow down advancements in lung cancer treatment options but also create obstacles for healthcare professionals striving to provide the best care for patients battling this serious illness.

Market Trends of the Global Lung Cancer Therapeutics Market

The global lung cancer therapeutics market is witnessing a significant shift towards personalized medicine, characterized by the integration of genetic profiling and biomarkers in treatment design. This transformative approach enhances the effectiveness of therapies while minimizing adverse effects, thereby addressing the unique characteristics of each patient's cancer. As a result, there is a growing demand for targeted therapies and immunotherapies that are specifically aligned with individualized patient profiles. This trend not only represents a fundamental change in the treatment paradigm but also emphasizes the need for ongoing advancements in research and technology to optimize patient outcomes in lung cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Lung Cancer Therapeutics Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic
• Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
• Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
• Chemotherapy
• Others

Global Lung Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)

Global Lung Cancer Therapeutics Market Size by Type of Molecule & CAGR (2026-2033)

• Market Overview
• Small molecules
• Biologics

Global Lung Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Lung Cancer Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multikinase Inhibitors
• Others

Global Lung Cancer Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Lung Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • US
  • Canada
• Europe (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy, Cancer Type, Type of Molecule, Distribution Channel, Drug Class, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations